

## Leading medical advisory board established to capitalise on TGA decision to reschedule cannabis

- **Members include Academic Director of the Lambert Initiative Prof. Iain McGregor, Head of Neurology at Gold Coast University Hospital Assoc. Prof. Arman Sabet, Dean of Sydney Pharmacy School Prof. Andrew McLachlan AM and ex Cancer Council CEO Prof. Ian Olver AM**
- **Board appointment coincides with the Therapeutic Goods Administration’s decision dated 15 December 2020 to down schedule CBD products to Scheduled 3 (pharmacist only) medicines**
- **Decision allows for low dose cannabidiol (CBD) products containing up to 150mg/day to be sold over-the-counter to consumers without a prescription**
- **Development broadens Bod’s addressable market and will assist with CBD product uptake across Australia**
- **Board’s immediate focus will be to review and evaluate the product registration pathways**

**Sydney, Australia – 16 December 2020:** Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited (“Bod”, or “the Company”) (ASX: BDA) is pleased to advise that it has established a leading medical advisory board comprised of internationally recognised physicians and researchers that will assist Bod to progress opportunities in the Australian market.

Bod’s medical advisory board includes Academic Director of the Lambert Initiative at the University of Sydney Professor Iain McGregor, Head of neurology at the Gold Coast University Hospital Associate Professor Arman Sabet MD, Head of School and Dean at Sydney Pharmacy School, University of Sydney Professor Andrew McLachlan AM and Professorial Research Fellow in the School of Psychology at the University of Adelaide Professor Ian Olver AM. A detailed biography for each member is included overleaf.

Each board member is highly experienced in their respective professional field and their extensive experience in differing areas of therapeutics will be instrumental as Bod actively pursues a number of initiatives associated with cannabis therapeutics.

The appointment of the medical advisory board follows the decision made by the Therapeutic Goods Administration (“TGA”) (tga.gov.au) regarding the rescheduling of cannabinoid (“CBD”) products to Schedule 3 (Pharmacist Only) medicines.

The decision, which was announced 15 December 2020, will allow CBD products that contain up to a maximum of 150mg/day, for use in adults that have been approved by the TGA, to be supplied over-the-counter by a pharmacist, without a prescription. The decision limits over-the-counter supply to only those products that are approved by the TGA and included on the Australian Register of Therapeutic Goods (ARTG). Medicines not included on the ARTG will be known as unapproved medicines, which can continue to be accessed via the Special Access Scheme or Approved Prescriber Scheme on a prescription only basis. The decision also outlines additional limits on dosage form and packaging requirements, including pack size and child resistant closures<sup>1</sup>.

This is a landmark ruling and considerably broadens Bod’s addressable market. The Company anticipates that the regulatory shift will greatly assist with the uptake of CBD products in Australia.

The immediate focus of Bod’s advisory board will be to progress product registration for a Schedule 3 low dose CBD product by reviewing and assessing the product registration pathways to determine the suitable registration pathway for Bod’s product. The board will also assist with R&D and other product development initiatives.

Should Bod be successful in registering a product, the Company will aim to market, sell and distribute it in collaboration with exclusive global partner Health and Happiness Group Limited (HKSE: 1112), under the leading Swisse Wellness brand.

Bod is a cannabis centric healthcare company. With a global focus and a mission to innovate and transform the way we live and enjoy life. Delivering premium, proven and trusted products for both the consumer markets and medical markets. Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications with education, research and knowledge.

### CAPITAL STRUCTURE

ASX code **BDA**  
 Shares on issue 91.4m  
 Market Capitalisation ~\$52.5m

### BOARD & MANAGEMENT

Mr Mark Masterson  
 Non-Executive Chairman

Ms Jo Patterson  
 Chief Executive Officer

Mr Akash Bedi  
 Non-Executive Director

Mr George Livery  
 Non-Executive Director

Mr Patrice Malard  
 Non-Executive Director

Mr Simon O’Loughlin  
 Non-Executive Director

Mr Stephen Kelly  
 Company Secretary

### CONTACT

Level 1, 377 New South Head Rd  
 Double Bay, NSW 2028

T +612 9199 5018

E info@bodaustralia.com.au

### **Commentary:**

**CEO Jo Patterson said:** *“The TGA’s decision to reschedule CBD products to over the counter medicines marks a major step forward for the sale of CBD in Australia and we are very confident that the establishment of our medical advisory board leaves the Company very well placed to capitalise.”*

*“Bod is currently exploring a number of opportunities to launch CBD products under both its medicinal cannabis division, as well as its consumer focused CBD and hemp product vertical. We will work with our newly established board to progress opportunities on both sides of the business, ensuring we have considerable optionality to drive revenue growth. We look forward to leveraging their expertise in the coming months to unlock opportunities that will further position Bod as a leading medicinal cannabis company.”*

**Professor Iain McGregor PhD said:** *“As medicinal cannabis and CBD become increasingly accepted in Australia, it is great to see companies like Bod that are dedicated to developing evidence-based cannabinoid therapeutics. I am looking forward to supporting them in this endeavor.”*

**Associate Professor Arman Sabet MD said:** *“It is a great pleasure to join Bod’s medical advisory board. Bod’s approach to partnering with leading research organisations and hospitals to find alternative solutions to treat unaddressed chronic health disorders presents a very exciting opportunity.”*

**Professor Andrew McLachlan AM, PhD said:** *I look forward to working with Bod and the other experienced Board members to further our understanding of how patients might benefit from Bod’s cannabis medicines.”*

**Professor Ian Olver AM, MD, PhD said:** *“Bod should be commended for partnering with experienced researchers and clinicians to advise on the development of their cannabis therapeutic. I am looking forward to assisting Bod with their strategic approach.”*

### **Medical advisory board members:**

**Professor Iain McGregor PhD** is a psychopharmacologist and the academic director of the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney. The Lambert Initiative explores the therapeutic potential of medicinal cannabis and cannabinoids. He has extensive experience in the scientific research of drug development, behavioural psychology, medicinal chemistry, toxicology, and preclinical and clinical trials. Professor McGregor is also involved in community education, regulatory change, compassionate access and the legal defence of people using medicinal cannabis on the grounds of medical necessity.

**Associate Professor Arman Sabet MD, FRACP** is a medical doctor and the Head of the Neurology Department at Gold Coast University Hospital and an Associate Professor of Neurology at Griffith University. Dr Sabet specialises in the treatment and management of neurological disorders, with a special interest in the utility of medicinal cannabis in clinical settings to help give patients the improved quality of life. Dr Sabet will provide crucial clinical insight and valuable expertise into neurological disorders.

**Professor Andrew McLachlan AM, PhD** is Head of School and Dean at the Sydney Pharmacy School, The University of Sydney. He is a trained pharmacist, university academic and scientific researcher with experience in clinical pharmacology and the quality use of medicines. Professor McLachlan is the former chair of a human research ethics committee and serves on Australian government committees related to medicines policy, evaluation, regulation and antidoping. He will provide invaluable expertise on clinical pharmaceutical research as well as the processes around drug development.

**Professor Ian Olver AM, MD, PhD** is currently a Professorial Research Fellow in the School of Psychology at the University of Adelaide. Trained as a medical oncologist and bioethicist, his current research focuses on supportive care in cancer and psycho-oncology. Professor Olver was previously CEO of Cancer Council Australia and Clinical Director of the Royal Adelaide Hospital Cancer Centre. His extensive experience and history in oncology practice and research will be invaluable for the research and development of cannabinoid therapeutics.

- ENDS -

## ABOUT BOD AUSTRALIA

**Bod Australia Limited (ASX:BDA)** Bod is a cannabis centric healthcare company.

With a global focus and a mission to innovate and transform the way we live and enjoy life.

Delivering premium, proven and trusted products for both the consumer markets and medical markets.

Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications through education, research and trials.

**This announcement was authorised for release by the Board of Directors of Bod Australia Limited.**

**For more information please contact:**

Jo Patterson  
Chief Executive Officer  
[info@bodaustralia.com](mailto:info@bodaustralia.com)  
+61 2 9199 5018

Henry Jordan  
Six Degrees Investor Relations  
[henry.jordan@sdir.com.au](mailto:henry.jordan@sdir.com.au)  
+61 431 271 538

---

<sup>i</sup> <https://www.tga.gov.au/media-release/over-counter-access-low-dose-cannabidiol>